{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:20:09Z","timestamp":1790014809044,"version":"4.0.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder characterized by obesity, insulin resistance, and cardiometabolic risks. Lifestyle intervention is first-line therapy, but drug therapy is often necessary. Common treatments include metformin, myoinositol, and glucagon-like peptide-1 (GLP-1) receptor agonists. The comparative metabolic efficacy of these treatments remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and network meta-analysis (NMA) of randomized controlled trials (RCTs) according to PRISMA-NMA guidelines. Eligible studies recruited non-menopausal women with PCOS and evaluated GLP-1 receptor agonists, metformin, or myoinositol (\u00b1 folic acid [FA]) alone or in combination versus placebo or active comparators. The primary outcome was body weight change, while secondary outcomes included body mass index (BMI), waist circumference, and Homeostasis Model Assessment for Insulin Resistance (HOMA-IR). Outcomes were synthesized using a frequentist random-effects NMA, and the CINeMA framework was used to assess certainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixteen RCTs were included. GLP-1 + metformin was the most effective intervention for weight reduction (MD \u22125.58 kg; 95% CI \u22128.57 to \u22122.59) and BMI decrease (MD \u22122.17; 95% CI \u22122.77 to \u22121.58). GLP-1 monotherapy also showed decreases in weight (MD \u22125.22 kg) and BMI (MD \u22122.00). Waist circumference was significantly reduced by GLP-1 alone (MD \u22124.70 cm). None ofthe interventions showed significant effects on HOMA-IR, and results were marked by heterogeneity. Sensitivity analyses confirmed robustness for weight and BMI outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GLP-1 receptor agonists combined with metformin appear to be the most effective pharmacologic therapies for anthropometric improvement, specifically body weight and BMI reduction, in women with PCOS. These conclusions are limited to anthropometric and metabolic parameters, reproductive, endocrine, and patient-centered outcomes were not evaluated in this analysis and therefore no claims of overall superiority in PCOS management can be made. Further long-term and head-to-head RCTs including a broader range of outcomes are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/osf.io\/zyhws\/<\/jats:ext-link>\n                      , identifier 10.17605\/OSF.IO\/ZYHWS\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1833904","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:22:44Z","timestamp":1783052564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Asad","family":"Omarion","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaman","family":"Ayasa","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Omarion","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batoul","family":"Jayouse","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University","place":["Jerusalem, Palestine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Ayesh","sequence":"additional","affiliation":[{"name":"Deaconess Clinic Endocrinology, Deaconess Health System","place":["Evansville, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","article-title":"Polycystic ovary syndrome (PCOS)","year":"","DOI":"10.55349\/ijmsnr.20255139"},{"key":"B2","first-page":"5411","article-title":"Polycystic ovary syndrome","volume":"12","year":"2023","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad463","article-title":"International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2023","volume":"108","author":"Teede","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/ijwh.s70314","article-title":"Complications and challenges associated with polycystic ovary syndrome","volume":"13","author":"Palomba","year":"2021","journal-title":"Int J Womens Health"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1530\/eje-13-0797","article-title":"Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome","volume":"170","author":"Jensterle Sever","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"16512","DOI":"10.1038\/s41598-025-99622-4","article-title":"Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials","volume":"15","author":"Lin","year":"2025","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1159\/000536163","article-title":"Myo-inositol effects in women with polycystic ovary syndrome","volume":"20","author":"Unfer","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v106.i02","article-title":"netmeta: An R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"J Stat Softw"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PloS Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1156521","article-title":"Efficacy of beinaglutide plus metformin versus metformin alone in obese women with polycystic ovary syndrome","volume":"14","author":"Wen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.945609","article-title":"Metformin versus metformin plus liraglutide in patients with polycystic ovary syndrome","volume":"13","author":"Xing","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2022.04.027","article-title":"Liraglutide 3.0 mg for weight management in women with polycystic ovary syndrome","volume":"118","author":"Elkind-Hirsch","year":"2022","journal-title":"Fertil Steril"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000001712","article-title":"Exenatide combined with metformin in overweight women with polycystic ovary syndrome","volume":"134","author":"Ma","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/xce.0000000000000044","article-title":"Metformin versus myo-inositol in polycystic ovary syndrome","volume":"45","author":"Soldat-Stankovi\u0107","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa692","article-title":"Exenatide, metformin, or both for prediabetes in women with polycystic ovary syndrome","volume":"106","author":"Tao","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ18-0153","article-title":"Effects of exenatide and metformin on zinc-\u03b12-glycoprotein levels in women with polycystic ovary syndrome","volume":"66","author":"Zheng","year":"2019","journal-title":"Endocr J"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1080\/09513590.2018.1540570","article-title":"Comparison of myo-inositol and metformin on metabolic and hormonal parameters in women with polycystic ovary syndrome","volume":"35","author":"Shokrpour","year":"2019","journal-title":"Gynecol Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13053","article-title":"Effect of liraglutide on ectopic fat in polycystic ovary syndrome","volume":"20","author":"Fr\u00f8ssing","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12902-017-0155-9","article-title":"Low-dose liraglutide combined with metformin versus high-dose liraglutide alone in obese women with polycystic ovary syndrome","volume":"17","author":"Jensterle","year":"2017","journal-title":"BMC Endocr Disord"},{"key":"B25","article-title":"Effects of metformin therapy in women with polycystic ovary syndrome","volume":"48","author":"Zahra","year":"2016","journal-title":"Horm Metab Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4103\/2305-0500.390300","article-title":"Myo-inositol versus metformin in infertile women with polycystic ovary syndrome","volume":"12","author":"Nguyen","year":"2023","journal-title":"Asian Pac J Reprod"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3390\/metabo12121183","article-title":"Myo-inositol compared with metformin in women with polycystic ovary syndrome","volume":"12","author":"Ravn","year":"2022","journal-title":"Metabolites"},{"key":"B28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.obmed.2017.06.003","article-title":"Exenatide versus metformin in overweight women with polycystic ovary syndrome","volume":"7","author":"Zheng","year":"2017","journal-title":"Obes Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3081","article-title":"Metformin enhances the effects of liraglutide in obese women with polycystic ovary syndrome","volume":"11","author":"Jensterle","year":"2016","journal-title":"Exp Ther Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/bf03401383","article-title":"Long-acting liraglutide in newly diagnosed obese women with polycystic ovary syndrome","volume":"15","author":"Jensterle","year":"2016","journal-title":"Hormones (Athens)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nature13270","article-title":"Metformin suppresses hepatic gluconeogenesis through a redox-dependent mechanism","volume":"510","author":"Madiraju","year":"2014","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tem.2018.09.001","article-title":"Inositol in polycystic ovary syndrome: a physiology-based approach","volume":"29","author":"Lagan\u00e0","year":"2018","journal-title":"Trends Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz140","article-title":"Effects of GLP-1 analogs on appetite, energy intake, and body fat distribution","volume":"105","author":"Kadouh","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/2042018820938305","article-title":"A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome","volume":"11","author":"Abdalla","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa285","article-title":"Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists","volume":"105","author":"Cena","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5915","DOI":"10.3390\/jcm12185915","article-title":"Do GLP-1 analogs have a place in the treatment of PCOS? New insights and promising therapies","volume":"12","author":"Szczesnowicz","year":"2023","journal-title":"J Clin Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2018.1505848","article-title":"The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls","volume":"35","author":"Kahal","year":"2019","journal-title":"Gynecol Endocrinol"},{"key":"B38","first-page":"99622","article-title":"Glucagon-like peptide-1 receptor agonists in women with polycystic ovary syndrome: a randomized controlled trial","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.88216","article-title":"Revisiting metformin in the management of polycystic ovary syndrome (PCOS)","volume":"17","author":"Telagarapu","year":"2025","journal-title":"Cureus"}],"updated-by":[{"DOI":"10.3389\/fendo.2026.1932302","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000}}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1833904\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:34:15Z","timestamp":1784550855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1833904\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":39,"alternative-id":["10.3389\/fendo.2026.1833904"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1833904","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"article-number":"1833904"}}